The Chulabhorn Royal Academy has opened Thailand’s first cancer drug manufacturing facility, certified under the globally recognized Good Manufacturing and Distribution Practices (GMDP PIC/s). Located at the Phimanmas Residence in Chon Buri’s Sattahip district, the facility marks a significant step in strengthening Thailand’s pharmaceutical production capabilities.
The initiative was led by Professor Dr. Chulabhorn Walailak, president of the Chulabhorn Royal Academy and member of the Thai royal family. She identified the need to improve access to effective cancer treatments and aimed to link scientific research with pharmaceutical manufacturing to support national health security.
The four-story facility includes production areas, engineering systems, quality control laboratories, and a data management center. It uses OEB5-level containment equipment to maintain high safety standards for workers, protect the environment, and ensure drug quality.
One of the first medications produced at the facility is IMCRANIB 100, a targeted cancer therapy for leukemia, gastrointestinal cancers, and rare skin cancers. The drug has been approved by Thailand’s Food and Drug Administration and is scheduled for inclusion in the public health system by the end of 2025.
According to facility director Dr. Watchara Kanjanagwinakul, the plant can manufacture between 30,000 and 150,000 tablets per production cycle. Plans are in place to increase output and expand the range of cancer drugs produced.
This development is expected to lower dependence on imported medicines, reduce treatment costs, and improve access to essential medications. It also contributes to advancing pharmaceutical knowledge and supports the long-term sustainability of Thailand’s public health system.
(Source: Thethaiger)
